|
Citation
|
Schwarz ES, Buchanan J, Aldy K, Shulman J, Krotulski A, Walton S, Logan B, Wax P, Campleman S, Brent J, Culbreth R, Manini AF. MMWR Morb. Mortal. Wkly. Rep. 2024; 73(30): 672-674. |
|
Abstract
|
What is already known about this topic?
Medetomidine, a veterinary anesthetic drug, is an emerging adulterant detected in illicit drugs, drug paraphernalia, and overdoses.
What is added by this report?
During August 2022-July 2023, medetomidine was detected among five patients along with xylazine, fentanyl, and illicit opioids. No permanent sequelae were reported. All patients received naloxone; however, only two received naloxone kits at discharge, and only one was referred for addiction treatment.
What are the implications for public health practice?
Medetomidine is an emerging adulterant detected in illicit drugs; further investigation is important to better understand the clinical effects of medetomidine and other novel adulterants. Programs to improve addiction treatment and naloxone distribution are needed.
Medetomidine, a canine veterinary agent used for its anesthetic and analgesic properties, is an emerging adulterant detected in illicit drugs and drug paraphernalia. Medetomidine is a racemic mixture of two optical isomers, levomedetomidine and dexmedetomidine; the pharmacologic effects are caused by dexmedetomidine, an alpha-2 agonist similar to xylazine (1). Medetomidine is not approved for human use. Xylazine, a well-described opioid adulterant, is associated with multiple adverse effects, including soft tissue wounds* (2). Whereas xylazine is not approved for human use, dexmedetomidine is used in hospitals as a sedative and analgesic. Dexmedetomidine is considered safe for sedation during certain procedures† (3) and is not associated with wounds when administered intravascularly or intramuscularly in hospitals. Medetomidine has been detected in samples of street-level drugs beginning in 2022 (4). Medetomidine is increasingly found in the drug supply across the United States and Canada and was associated with overdoses in April and May 2024 in Philadelphia, Pittsburgh, and Chicago.§ The recent overdose outbreaks in Philadelphia, Pittsburgh, and Chicago highlight the need to understand symptoms associated with medetomidine use and overdose. This report describes the detection of medetomidine from illicit agents among patients evaluated in an emergency department (ED) after suspected opioid overdoses, none of whom had received medetomidine as part of clinical care.
Investigation and Outcomes
Data for this analysis are from the Toxicology Investigators Consortium Fentalog Study Group, a 2020-2025 study of patients aged >18 years evaluated in 10 EDs in nine states after a suspected opioid overdose as part of ongoing activities to determine the role and prevalence of novel substances in these overdoses. Comprehensive toxicologic testing for the presence of approximately 1,200 drugs and metabolites, including an array of novel psychoactive substances and adulterants, was performed on residual blood samples using liquid chromatography quadrupole time-of-flight mass spectrometry. Patients who received a positive medetomidine test result were included. Additional case information was obtained through chart review.¶ A waiver of consent was obtained for specimen collection. This activity was approved centrally by Western Institutional Review Board, and locally at each participating institution.
During September 2020-December 2023, a total of 1,331 blood samples** collected from persons evaluated in participating EDs for a suspected opioid overdose were analyzed. Medetomidine was detected among five patients (0.4%) from three states (Missouri, Colorado, and Pennsylvania) during August 2022-July 2023 (Table). Patients A and B were initially hypotensive (systolic/diastolic blood pressures = 64/37 mmHg and 96/60 mmHg, respectively), but neither had bradycardia. Four patients were intentionally using opioids recreationally. All patients received naloxone (median total dose = 2 mg), one of whom received an infusion. All patients' neurologic exams were normal by 4 hours after arrival in an ED. Patient C, a man, aged 30-39 years, had an elevated troponin concentration but was discharged 4 hours after arrival. Patients A and B initially had acidosis (pH = 7.29 and 7.19, respectively). Patient B, a woman, aged 20-29 years, experienced respiratory and hemodynamic complications shortly after arrival and received positive test results for methamphetamine and olanzapine, but negative test results for opioids; she was hospitalized for 18 days. Comprehensive blood testing confirmed the presence of fentanyl among three patients, illicit benzodiazepines among three, stimulants among three, xylazine among three, and nitazene opioids among two. Only two patients were documented to have received naloxone kits at discharge, and only one was referred for addiction treatment.
Preliminary Conclusions and Actions
These clinical findings are the first to illustrate the effects of medetomidine among a series of patients who used illicit drugs. Codetection with fentanyl is consistent with medetomidine use as an adulterant. Although knowledge about medetomidine's short- and long-term effects is limited, permanent sequelae were not reported in any of the patients in this analysis. Xylazine was detected in samples from three patients, suggesting that medetomidine and xylazine exposure might occur from a concomitant drug exposure. Information regarding wounds was not recorded in the hospital chart in this cohort.
Hospitals are improving their treatment of patients with substance use disorders (5); however, continued support is required, given the low prevalence of naloxone distribution and addiction medicine referrals identified in this sample. Medetomidine is an emerging adulterant, associated in this report with fentanyl and other novel psychoactive substances, that is not detected as part of a standard urine drug screen. Although long-term, permanent sequelae were not reported, further investigation into the clinical and long-term effects of medetomidine is warranted.
Language: en |